Grant: Knowledge Synthesis Grant
Université Laval
$100,000.00
Diagnostic Test Accuracy Review : Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women.
FY 2014-15
Summary
Each year over 450,000 Canadian women become pregnant and face difficult decisions about prenatal screening for Down syndrome. The current biochemical+ultrasound screening tests reach a sensitivity of 85% with a false positive rate of 4%. The large number of amniocenteses needed to be performed on women with a positive screening test causes the loss of about 50 normal babies each year. In the recent years genomic non-invasive prenatal testing (NIPT) methods using plasma circulating cell-free DNA for the detection of common fetal aneuploidies in pregnant women have been reported to have, in high-risk women, a sensitivity >99% and a lower false positive rate (<0.5%). There is little data up to now on the performances of NIPT in women at normal risk (i.e. with no prior positive screening result). Provincial governments are under pressure to assume the costs of NIPT as a triage test after a positive biochemical prenatal screening test, to select women who would be offered amniocentesis for a fetal karyotype. Ontario has already decided to pay for the test even in the absence of large data sets independent from the vendors of the commercial assays. Our Knowledge Users (KUs) which comprise Chairs of provincial committees for prenatal screening, have knowledge needs in order to provide optimal care to pregnant women in Canada. Consequently, in response to our KUs’ needs, our goal is to ensure that Canadian women and health care providers have the best evidence to support informed value-based decisions regarding prenatal screening. More specifically, we will determine the diagnostic test accuracy (DTA) of NIPT methods using plasma circulating cell-free DNA for the detection of common fetal aneuploidies in pregnant women and ensure that the resulting evidence is translated into the needed knowledge tool(s). Our overarching conceptual model is the knowledge to action framework (knowledge-to-action framework Graham et al ). First, using Cochrane high standard methods for DTA systematic reviews and meta-analyses, we will identify primary studies on NIPT used as a triage test (after a positive screening result) before amniocentesis, as a first tier test (in place of the current screening tests) and as a diagnostic test that could replace amniocentesis. We will use the QUADAS2 criteria to assess the quality of evidence and perform a meta-analysis of NIPT performances in these three different applications. We will identify potential sources of heterogeneity that could influence test performance and perform sensitivity analyses. Second, we will convene a KU meeting in which we will review the evidence and assess their opinion on the needed knowledge tool(s). With help from our KUs, we will enrol participants from the following groups: pregnant women, parents of DS cases, GPs, OBGYNs, laboratory specialists, public health officers. We will conduct homogenous groups for each sub-group, and cover two provinces (BC, Québec). Overall, our Team is an optimal mix of KU and researchers with a common goal: providing Canadian women with the best evidence regarding NIPT for prenatal screening. Expected results will provide independent assessment of all NIPT methods published up to now. Thus, our KUs in the different provincial health care jurisdictions are asking for a systematic review on NIPT. In addition, our proposal will provide the needed knowledge tools so Canadian women and their clinicians make informed value-based decisions.
Department
Program
Knowledge Synthesis Grant
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
319520
Name
Rousseau François
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Clinical
Prcname2
Knowledge Synthesis Grant
Projecttitle
Diagnostic Test Accuracy Review : Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women.
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Knowledge Synthesis Grant
Keyworddelim
Chromosomal Aneuploidy; Diagnostic Test Accuracy Review; Genomic-Based Fetal Testing; Next-Generation Sequencing; Non-Invasive Prenatal Testing
Abstract
<html>
<body>Each year over 450,000 Canadian women become pregnant and face difficult decisions about prenatal screening for Down syndrome. The current biochemical+ultrasound screening tests reach a sensitivity of 85% with a false positive rate of 4%. The large number of amniocenteses needed to be performed on women with a positive screening test causes the loss of about 50 normal babies each year. In the recent years genomic non-invasive prenatal testing (NIPT) methods using plasma circulating cell-free DNA for the detection of common fetal aneuploidies in pregnant women have been reported to have, in high-risk women, a sensitivity >99% and a lower false positive rate (<0.5%). There is little data up to now on the performances of NIPT in women at normal risk (i.e. with no prior positive screening result). Provincial governments are under pressure to assume the costs of NIPT as a triage test after a positive biochemical prenatal screening test, to select women who would be offered amniocentesis for a fetal karyotype. Ontario has already decided to pay for the test even in the absence of large data sets independent from the vendors of the commercial assays. Our Knowledge Users (KUs) which comprise Chairs of provincial committees for prenatal screening, have knowledge needs in order to provide optimal care to pregnant women in Canada. Consequently, in response to our KUs’ needs, our goal is to ensure that Canadian women and health care providers have the best evidence to support informed value-based decisions regarding prenatal screening. <br> More specifically, we will determine the diagnostic test accuracy (DTA) of NIPT methods using plasma circulating cell-free DNA for the detection of common fetal aneuploidies in pregnant women and ensure that the resulting evidence is translated into the needed knowledge tool(s). <br> Our overarching conceptual model is the knowledge to action framework (knowledge-to-action framework Graham et al ). First, using Cochrane high standard methods for DTA systematic reviews and meta-analyses, we will identify primary studies on NIPT used as a triage test (after a positive screening result) before amniocentesis, as a first tier test (in place of the current screening tests) and as a diagnostic test that could replace amniocentesis. We will use the QUADAS2 criteria to assess the quality of evidence and perform a meta-analysis of NIPT performances in these three different applications. We will identify potential sources of heterogeneity that could influence test performance and perform sensitivity analyses. Second, we will convene a KU meeting in which we will review the evidence and assess their opinion on the needed knowledge tool(s). With help from our KUs, we will enrol participants from the following groups: pregnant women, parents of DS cases, GPs, OBGYNs, laboratory specialists, public health officers. We will conduct homogenous groups for each sub-group, and cover two provinces (BC, Québec). <br> Overall, our Team is an optimal mix of KU and researchers with a common goal: providing Canadian women with the best evidence regarding NIPT for prenatal screening. <br> Expected results will provide independent assessment of all NIPT methods published up to now. Thus, our KUs in the different provincial health care jurisdictions are asking for a systematic review on NIPT. In addition, our proposal will provide the needed knowledge tools so Canadian women and their clinicians make informed value-based decisions.</body>
</html>
Competitiondate
201411
Approvedterm2
1 yr 0 mth
Pinamesdelim
Forest, Jean-Claude; Langlois, Sylvie F; Légaré, France; Turgeon, Alexis F; Rousseau, François
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~